Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer - A Longitudinal Study

被引：0
|
作者：
Dani, Lara [1 ,2 ]
Selickaja, Sandra [3 ,4 ]
Galindo-Feria, Angeles Shunashy [5 ]
Svensson, John [1 ]
Venalis, Paulius [6 ]
Leonard, Dag [7 ]
Hemberg, Malin [8 ]
Hanna, Balsam [9 ]
Lundberg, Ingrid E. [10 ]
Holmqvist, Marie [1 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Karolinska Univ Hosp, Stockholm, Sweden
[3] State Res Inst Innovat Med, Vilnius, Lithuania
[4] Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania
[5] Karolinska Inst, Karolinska Univ Hosp, Stockholm, Sweden
[6] Karolinska Inst, Dept Med, Ctr Mol Med, Stockholm, Sweden
[7] Uppsala Univ, Dept Rheumatol, Uppsala, Sweden
[8] Falu Lasarett, Rheumatol Unit, Falun, Sweden
[9] Sahlgrens Univ Hosp, Dept Rheumatol, Gothenburg, Sweden
[10] Karolinska Inst, Karolinska Univ Hosp, Div Rheumatol, Dept Med Solna, Stockholm, Sweden
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0696
引用
收藏
页码：1412 / 1413
页数：2
相关论文
共 50 条
  • [41] Case Series: The Challenge of Using Immune Checkpoint Inhibitors in Anti-Transcriptional Intermediary Factor 1 Antibody-Positive Dermatomyositis
    Chen, Liang
    Fallavollita, Sabrina
    Sakr, Lama
    Wang, Hangjun
    Pusztaszeri, Marc
    Esfahani, Khashayar
    Pollak, Michael N.
    Hudson, Marie
    Leclair, Valerie
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2025, 28 (01)
  • [42] Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis
    Zhang, Lining
    Yang, Hanbo
    Yang, Hongxia
    Liu, Hongyan
    Tian, Xiaolan
    Jiang, Wei
    Peng, Qinglin
    Wang, Guochun
    Lu, Xin
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 55
  • [43] Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity.
    Fujimoto, Manabu
    Murakami, Akihiro
    Kurei, Shunsuke
    Kuwajima, Akiko
    Fujisawa, Yasuhiro
    Kawakami, Atsushi
    Mishima, Michiaki
    Sato, Shinji
    Seishima, Mariko
    Suda, Takafumi
    Mimori, Tsuneyo
    Takehara, Kazuhiko
    Kuwana, Masataka
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S551 - S551
  • [44] IN THE ABSENCE OF IDIOPATHIC INFLAMMATORY MYOPATHY, IS THE PRESENCE OF ANTI-TRANSCRIPTIONAL INTERMEDIARY FACTOR-1 GAMMA CLINICALLY RELEVANT FOR MALIGNANCY?
    Cotton, Caroline V.
    Keymer, Catherine
    McLaren, Zoe
    RHEUMATOLOGY, 2022, 61
  • [45] Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis
    Sherman, Matthew A.
    Yang, Qingyuan
    Gutierrez-Alamillo, Laura
    Pak, Katherine
    Flegel, Willy A.
    Mammen, Andrew L.
    Rider, Lisa G.
    Casciola-Rosen, Livia A.
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 (04) : 631 - 637
  • [46] Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation
    Aggarwal, Rohit
    Oddis, Chester V.
    Goudeau, Danielle
    Fertig, Noreen
    Metes, Ilinca
    Stephens, Chad
    Qi, Zengbiao
    Koontz, Diane
    Levesque, Marc C.
    RHEUMATOLOGY, 2014, 53 (03) : 433 - 437
  • [47] Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report
    Kim, Yoonjoo
    Park, Dongil
    Choi, Song-Yi
    Chung, Chaeuk
    THORACIC CANCER, 2022, 13 (19) : 2808 - 2811
  • [48] Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital
    Suga, Takeshi
    Oiwa, Hiroshi
    Ishida, Michihiro
    Iwamoto, Yasuo
    CLINICAL RHEUMATOLOGY, 2022, 41 (09) : 2803 - 2808
  • [49] Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital
    Takeshi Suga
    Hiroshi Oiwa
    Michihiro Ishida
    Yasuo Iwamoto
    Clinical Rheumatology, 2022, 41 : 2803 - 2808
  • [50] Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report
    Kim, Yoonjoo
    Chung, Chaeuk
    Park, Dongil
    Choi, Song-Yi
    RESPIROLOGY, 2023, 28 : 295 - 296
12345